BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 17848650)

  • 1. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
    JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
    Toole JF; Malinow MR; Chambless LE; Spence JD; Pettigrew LC; Howard VJ; Sides EG; Wang CH; Stampfer M
    JAMA; 2004 Feb; 291(5):565-75. PubMed ID: 14762035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
    Ebbing M; Bleie Ø; Ueland PM; Nordrehaug JE; Nilsen DW; Vollset SE; Refsum H; Pedersen EK; Nygård O
    JAMA; 2008 Aug; 300(7):795-804. PubMed ID: 18714059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study.
    Jamison RL; Hartigan P; Gaziano JM; Fortmann SP; Goldfarb DS; Haroldson JA; Kaufman J; Lavori P; McCully KS; Robinson K
    Clin Trials; 2004; 1(5):451-60. PubMed ID: 16279283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.
    Albert CM; Cook NR; Gaziano JM; Zaharris E; MacFadyen J; Danielson E; Buring JE; Manson JE
    JAMA; 2008 May; 299(17):2027-36. PubMed ID: 18460663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
    Mann JF; Sheridan P; McQueen MJ; Held C; Arnold JM; Fodor G; Yusuf S; Lonn EM;
    Nephrol Dial Transplant; 2008 Feb; 23(2):645-53. PubMed ID: 18003666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
    ; Armitage JM; Bowman L; Clarke RJ; Wallendszus K; Bulbulia R; Rahimi K; Haynes R; Parish S; Sleight P; Peto R; Collins R
    JAMA; 2010 Jun; 303(24):2486-94. PubMed ID: 20571015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer incidence and mortality after treatment with folic acid and vitamin B12.
    Ebbing M; Bønaa KH; Nygård O; Arnesen E; Ueland PM; Nordrehaug JE; Rasmussen K; Njølstad I; Refsum H; Nilsen DW; Tverdal A; Meyer K; Vollset SE
    JAMA; 2009 Nov; 302(19):2119-26. PubMed ID: 19920236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
    Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J
    Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial.
    Saposnik G; Ray JG; Sheridan P; McQueen M; Lonn E;
    Stroke; 2009 Apr; 40(4):1365-72. PubMed ID: 19228852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for lowering plasma homocysteine levels in dialysis patients.
    Nigwekar SU; Kang A; Zoungas S; Cass A; Gallagher MP; Kulshrestha S; Navaneethan SD; Perkovic V; Strippoli GF; Jardine MJ
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD004683. PubMed ID: 27243372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Should patients with chronic renal insufficiency be treated with folic acid, vitamin B6 and vitamin B12?].
    Birn H
    Ugeskr Laeger; 2008 Mar; 170(11):933-7. PubMed ID: 18397619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial].
    Sánchez Alvarez JE; Pérez Tamajón L; Hernández D; Alvarez González A; Delgado P; Lorenzo V
    Nefrologia; 2005; 25(3):288-96. PubMed ID: 16053010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients.
    Sun Y; Lu CJ; Chien KL; Chen ST; Chen RC
    Clin Ther; 2007 Oct; 29(10):2204-14. PubMed ID: 18042476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
    Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
    Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.
    House AA; Eliasziw M; Cattran DC; Churchill DN; Oliver MJ; Fine A; Dresser GK; Spence JD
    JAMA; 2010 Apr; 303(16):1603-9. PubMed ID: 20424250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.
    Brady CB; Gaziano JM; Cxypoliski RA; Guarino PD; Kaufman JS; Warren SR; Hartigan P; Goldfarb DS; Jamison RL
    Am J Kidney Dis; 2009 Sep; 54(3):440-9. PubMed ID: 19628319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
    Righetti M; Serbelloni P; Milani S; Ferrario G
    Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins.
    Tremblay R; Bonnardeaux A; Geadah D; Busque L; Lebrun M; Ouimet D; Leblanc M
    Kidney Int; 2000 Aug; 58(2):851-8. PubMed ID: 10916110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.